• Logo
  • SBMUJournals

Prevalence of Chlamydia trachomatis and Mycoplasma genitalium in Patients with Benign and Malignant Ovarian Cancer by Nested PCR Method

Masoud Dadashi, Gita Eslami, Zohreh Ghalavand, Hossein Goudarzi, Fatemeh Fallah, Parviz Owlia, Zahra Zahirnia, Najmeh Ardeshiri
534

Views

PDF

Abstract

Background: Chlamydia trachomatis (C. trachomatis) and Mycoplasma genitalium (M. genitalium) are considered factors in cervical and ovarian cancer and are associated with flaky cell carcinoma of the cervix. The role of steady infection, leading to chronic inflammation, in the of ovarian cancer has received very little consideration, although a background of pelvic inflammatory disease (PID) is in a case-control study associate to higher risk for ovarian cancer. C. trachomatis, the most common and important cause of PID in the developed world is the genital and cervical infectious agent. The aim of this study was prevalence of C. trachomatis and M. genitalium in patients with ovarian cancer who referred to Imam Hossein Hospital of Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Materials and Methods: In this descriptive study that was conducted from January 2014 to April 2015, 124 samples were studied which obtained from patients with ovarian cancer who referred to medical centers of Shahid Beheshti University of Medical Sciences. After obtaining samples from ovarian cancer tissue by the pathologist, for extraction DNA, samples were transferred to the laboratory of university. To confirm the presence of C. trachomatis in samples of ovarian cancer, specific primers for the Major Outer Membrane Protein (MOMP) genes of C. trachomais, were designed and used Nested PCR method for detection of M. genitalium. Sequencing was performed on the PCR and Nested PCR product to confirm the presence of C. trachomatis and M. genitalium.

Results: Out of 124 samples of ovarian cancer, 62 (50%) samples were malignant cancer and 62 (50%) were benign cancer as control group. From 65 malignant samples 14 (22.5%) were Chlamydia trachomatis positive. None of the tissue samples of benign cancer of ovary were positive for C. trachomatis. Notably, none of the 124 ovarian samples were positive in the M. genitalium standard PCR assay.

Conclusion: The results suggest that the spread of C. trachomatis in the female with ovarian cancer may be common. This finding reflects a possible role of C. trachomatis in the carcinogenesis of ovarian tumors. C. trachomatis infection may play a relative role in the pathogenesis of ovarian carcinomas or it could facilitate its progression.


Keywords

Chlamydia trachomatis, Mycoplasma genitalium, Ovarian Cancer, Nested PCR

References

Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Practice and Research: Clinical Obstetrics and Gynecology. 2006;20(2):207–25.

Berchuck A, Schildkraut JM, Marks JR, Futreal PA. Managing hereditary ovarian cancer risk. Cancer. 1999;86(11):2517–24.

Weinberg RA. The rational treatment of cancer. In The biology of cancer. 1st edition. Edited by Garland Science. LLC: Taylor & Francis Group; 2007:725–95.

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008. GLOBOCAN 2008. Int J Cancer 2010. 127(12):2893–917.

Piek JM, Diest PJ, Verheijen RH. Ovarian carcinogenesis: an alternative hypothesis. Adv Exp Med Bio. 2008;622:79–87.

Shih M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. The American Journal of Pathology. 2004;164(5):1511–8.

Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih IM. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. The American Journal of Obstetrics and Gynecology. 2008;198(4):351–6.

Crum CP, Drapkin R, Miron A, et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Current Opinion in Obstetrics and Gynecology. 2007;19(1):3–9.

Mørch LS, Løkkegaard E, Andreasen AH, Krüger-Kjaer S, Lidegaard O. Hormone therapy and ovarian cancer. JAMA. 2009;302:298-305.

National Comprehensive Cancer Network. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Ovarian Cancer. 2009;v.2.

Jensen A, Sharif H, Frederiksen K, Kjaer SK. Use of fertility drugs and risk of ovarian cancer: Danish population based cohort study. BMJ. 2009;338:b249.

Berek JS, Chalas E, Edelson M, Moore DH, Burke WM, Cliby WA, et al. Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. Obstet Gynecol. 2010;116(3):733-43.

Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst. 1999;91:1459–57.

Cohen CR, Brunham RC. Pathogenesis of chlamydia induced pelvic inflammatory disease. Sex Transm Infect. 1999;75:21–4.

Shu XO, Gao YT, Yuan JM, et al. Dietary factors and epithelial ovarian cancer. Br J Cancer. 1989;59:92–6.

Paavonen J. Chlamydia trachomatis and cancer. Sex Transm Infect. 2001;77:154–6.

Idahl A, Lundin E, Jurstrand M, Kumlin U, Elgh F, Ohlson N, Ottander U. Chlamydia trachomatis and mycoplasma genitalium plasma antibodies in relation to epithelial ovarian tumors. Infect Dis Obstet Gynecol. 2011;824627.

Roberta B, Ness, Marc T, Caixia Sh, Robert C. Serologic Evidence of Past Infection with Chlamydia trachomatis, in Relation to Ovarian Cancer. Infectious Diseases Society of America. 2003;187:1147–52.

Felice V, David S, Cappello F, Farina F, Zummo G. Is chlamydial heat shock protein 60 a risk factor for oncogenesis? Cell Mol Life Sci. 2005;62:4-9.

Paavonen J, Karunakaran KP, Noguchi Y, et al. Serum antibody response to the heat shock protein 60 of Chlamydia trachomatis in women with developing cervical cancer. Am J Obstet Gynecol. 2003;189:1287-92.

Felice V, David S, Cappello F, Farina F, Zummo G. Is chlamydial heat shock protein 60 a risk factor for oncogenesis? Cell Mol Life Sci. 2005;62:4-9.

WHO, Global Prevalence and Incidence of Selected Curable Sexually Transmitted Infections. Overview and Estimates. World Health Organization, Geneva, Switzerland. 2001.

Thanapprapasr D, Wilailak S. Screening for Ovarian Cancer in Women, Ovarian Cancer - Clinical and Therapeutic Perspectives, Dr. Samir Farghaly (Ed.), ISBN: 978-953-307-810-6, InTech, 2012.

Arab M, Noghabaei G. Ovarian Cancer Incidence in Iran and the World, Preventative Gynecology Research Center (PGRC). Imam Hossein Medical Center. Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Ness RB, Goodman MT, Shen C, Brunham RC. Serologic evidence of past infection with Chlamydia trachomatis, in relation to ovarian cancer. J Infect Dis. 2003;187:1147-52.

Annika Lundin I, Jurstrand E, Kumlin M, Elgh U, Ohlson F, Ottander N. Chlamydia trachomatis and Mycoplasma genitalium plasma antibodies in relation to epithelial ovarian tumors, Infectious diseases in obstetrics and gynecology. 2011;1064-7449.

Weström L, Wølner-Hanssen P. Pathogenesis of pelvic inflammatory disease. Genitourin Med. 1993;69:9-17.

World Health Organization Task Force on the Prevention and Management of Infertility. Tubal infertility: serologic relationship to past chlamydial and gonococcal infection. Sex Transm Dis. 1995;22:71-7.

Barrett S, Taylor C. A review on pelvic inflammatory disease. Int J STD AIDS. 2005;16:715-20.

Haggerty CL. Evidence for a role of Mycoplasma genitalium in pelvic inflammatory disease. Curr Opin Infect Dis. 2008;21:65-9.

Carvalho JP, Carvalho FM. Is Chlamydia infected tubal fimbria the origin of ovarian cancer? Med Hypotheses. 2008;71:690-3.




DOI: https://doi.org/10.22037/nbm.v4i1.7666